CurrentCignaPolicy N/A

Hypertension - Clonidine Patches Drug Quantity Management Policy - Catapres TTS (clonidine transdermal system)

Defines drug quantity management limits and exception criteria for clonidine transdermal therapeutic system (Catapres-TTS and generics) for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyHypertension - Clonidine Patches Drug Quantity Management Policy - Catapres TTS (clonidine transdermal system)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateJun 19, 2024

Key ActionFollow quantity limits: retail max 4 patches/28 days and home delivery max 12 patches/84 days; document exceptions to support a 1-year approval.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4Retail max/28d

12Home delivery max/84d

1 yrAuth duration

3Patch strengths

Coverage and Exception Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Default quantity limits: For each clonidine TTS strength (0.1, 0.2, 0.3 mg/day) the retail maximum is 4 patches per 28 days and the home delivery maximum is 12 patches per 84 days.4 per 28 days retail; 12 per 84 days home delivery

See exceptions below.

Exceptions for 0.2 mg/day patch: If the patient requires two 0.2 mg/day patches applied simultaneously, approve up to 8 patches per 28 days (retail) or 24 patches per 84 days (home delivery).8 per 28 days retail; 24 per 84 days home delivery

Overrides are not recommended for patients changing the patch more frequently than every 7 days.

Exceptions for 0.3 mg/day patch: If the patient requires two 0.3 mg/day patches applied simultaneously, approve up to 8 patches per 28 days (retail) or 24 patches per 84 days (home delivery).8 per 28 days retail; 24 per 84 days home delivery

Overrides are not recommended for patients changing the patch more frequently than every 7 days.

No overrides recommended for clonidine 0.1 mg/day patch; overrides not recommended for changing patches more frequently than every 7 days.N/A

Any other exception is considered not medically necessary.

Overrides to the drug quantity limits are limited to the specific exception criteria listed for the 0.2 mg/day and 0.3 mg/day patches. For those strengths, an exception may be approved when the patient requires two patches to be applied simultaneously, in which case the approved quantity is 8 patches per 28 days (retail) or 24 patches per 84 days (home delivery). The policy explicitly states that overrides are not recommended for patients changing the patch more frequently than every 7 days.

All approvals granted under these exceptions are issued for a duration of 1 year, and documentation should support the clinical need for the exception at the time of review. Requests that do not meet the documented exception criteria will be evaluated against the standard Drug Quantity Management limits and are subject to denial.

What Providers Must Do

Billing Rule

Quantity limits and exception summary

Drug Quantity Limits: Retail maximum of 4 patches per 28 days and home delivery maximum of 12 patches per 84 days for each strength (0.1 mg/day, 0.2 mg/day, 0.3 mg/day). Exceptions to these quantity limits are covered as medically necessary only when the specific exception criteria are met (see criteria).

0.1 mg/day (Catapres-TTS-1): Retail Max = 4 patches/28 days; Home Delivery Max = 12 patches/84 days.
0.2 mg/day (Catapres-TTS-2): Retail Max = 4 patches/28 days; Home Delivery Max = 12 patches/84 days.
0.3 mg/day (Catapres-TTS-3): Retail Max = 4 patches/28 days; Home Delivery Max = 12 patches/84 days.

Prior Authorization

Titration guidance

Start clonidine transdermal therapy with the clonidine TTS-1 patch (delivers 0.1 mg clonidine/day for 1 week) and titrate according to clinical response. If blood pressure reduction is inadequate after 1–2 weeks, increase dose by adding another 0.1 mg/day patch or switch to a higher strength. When substituting from oral clonidine, be aware the patch effect may take 2–3 days to begin — gradually reduce prior oral antihypertensive therapy as clinically indicated to avoid loss of blood pressure control.

Initiation: begin with 0.1 mg/day (TTS-1) patch.
Titration: reassess at 1–2 weeks; increase by adding an additional 0.1 mg/day patch or move to higher strength as needed.
Oral-to-patch substitution: allow 2–3 days for patch onset; taper prior oral agents gradually.

Documentation Required

Approval duration and documentation

If the Drug Quantity Management rule is not met at point of service, coverage will be determined by the listed exception criteria and documentation. All approvals are provided for 1 year in duration. Documentation submitted must support medical necessity for any exception to the quantity limits.

Coverage when quantity limits exceeded is determined only by meeting exception criteria.
All approvals (including approved exceptions) are issued for 1 year.
Provide clinical documentation that justifies the need for quantities beyond the standard limits.

Clinical Background

Clonidine transdermal therapeutic system (Catapres‑TTS and generics) is a centrally acting alpha‑agonist indicated for the treatment of hypertension and may be used alone or in combination with other antihypertensive agents. The system delivers clonidine transdermally at available strengths of 0.1 mg/day, 0.2 mg/day, and 0.3 mg/day and is applied to intact, hairless skin once every 7 days. Dosing is titrated to clinical response; when switching from oral clonidine, gradual reduction of the prior dosage is advised because the full antihypertensive effect of the patch may be delayed by approximately 2–3 days after initial application.

Definitions

inv-09: Clonidine TTS (Catapres-TTS) — definitions

Device descriptionClonidine transdermal therapeutic system (Catapres‑TTS; generic) — a centrally acting alpha‑agonist transdermal patch used to treat hypertension.

Available strengths0.1 mg/day (TTS‑1), 0.2 mg/day (TTS‑2), 0.3 mg/day (TTS‑3).

Application intervalApply once every 7 days to a hairless area of intact skin on the upper outer arm or chest; use a different site for each new patch.

Packaging detailsEach strength supplied in cartons of 4 packets (1 patch per packet) with 4 adhesive covers; generics also available as single packets.

Titration/clinical notesInitiate with 0.1 mg/day patch and titrate per clinical response; if substituting from oral clonidine, antihypertensive effect may be delayed 2–3 days so gradual reduction of prior drug dosage is advised.